FDA Approves J&J’s Akeega for BRCA2-Mutated mCSPC, Marking a New Era in Precision Prostate Cancer Care
As reported on FiercePharma, Johnson & Johnson has secured a significant milestone in prostate cancer treatment with the FDA’s approval of Akeega for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer…
Continue Reading
FDA Approves J&J’s Akeega for BRCA2-Mutated mCSPC, Marking a New Era in Precision Prostate Cancer Care
